New Zealand markets closed

GlaxoSmithKline plc (GLAXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
22.970.00 (0.00%)
As of 03:40PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close22.97
Open22.97
Bid0.00 x 0
Ask0.00 x 0
Day's range22.97 - 22.97
52-week range16.50 - 23.47
Volume868
Avg. volume12,182
Market cap119.541B
Beta (5Y monthly)0.38
PE ratio (TTM)19.94
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.10 (5.15%)
Ex-dividend date18 Nov 2021
1y target estN/A
  • Motley Fool

    Should GlaxoSmithKline Have Accepted Unilever's $68 Billion Consumer Health Offer?

    In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether they think GlaxoSmithKline should have accepted Unilever's offer. Keith Speights: One of the big stories in recent days was that GlaxoSmithKline (NYSE: GSK) revealed that it turned down an offer of more than $68 billion from Unilever (NYSE: UL) to buy the combined consumer health unit of Glaxo and Pfizer (NYSE: PFE).

  • Zacks

    Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA

    Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.

  • Zacks

    Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition

    Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.